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Conclusion.
More children with HAdV genotype 7 infection required cidofovir treatment. HAdV pneumonia and ICU admission are potential risk factors for mortality despite cidofovir treatment.
Disclosures. All authors: No reported disclosures. Background. In the pre-acyclovir era, HSV CNS infection was associated with very high morbidity and mortality. Since antiviral drugs recommended for therapy and long-term prophylaxis improve outcomes, clinicians need to be able to clinically detect young infants most likely to have HSV to facilitate early initiation of therapy. Limited data exist on outcomes of infants who require prolonged therapy and those completing prophylaxis. The objective of this study was to identify clinical and laboratory features associated with HSV CNS disease and describe outcomes following antiviral therapy and prophylaxis.
Treatment Implications of Herpes
Methods. Infants <90 days old with a discharge diagnosis of meningitis or encephalitis from whom a virus was identified from cerebrospinal fluid (CSF) were included. These were identified using PICNICs retrospective database of microbiologically confirmed CNS infections detected January 2013 to December 2014. Clinical features and outcomes of HSV and non-HSV infection were compared.
Results. Of the 112 cases of viral infections, HSV accounted for 8 (7%) and enterovirus for 103 (92%). Eight (100%) HSV cases and 45 (43%) non-HSV cases presented at <21 days. Four (50%) HSV cases had no pleocytosis. HSV cases were more likely to require ICU admission (P = 0.016), present with seizures (P < 0.001) and have extra-CNS disease (P < 0.001). Among infants <3 weeks of age, seizures were more likely in HSV than non-HSV cases (4 (50%) vs. 4 (8%); P = 0.013). All HSV cases received acyclovir for a median of 23 days. Two (25%) remained PCR-positive at 21 days; these were treated for 51 and 42 days, respectively, until PCR negative or death (acyclovir resistance was confirmed postmortem). Four infants received suppressive acyclovir until 6 months, one of whom developed virologically proven CNS recurrence and subsequent infantile spasms. Neurodevelopmental morbidity (4 (57%) vs. 7 (7%)) was more likely in HSV than non-HSV (P = 0.003).
Conclusion. High levels of suspicion for viral infections must be maintained for young infants presenting with seizures in the first 3 weeks of life. CSF pleocytosis may often be absent. Resistance testing should be considered if PCR remains positive beyond 21 days. CNS recurrences may still occur beyond the recommended period of prophylaxis.
Disclosures. All authors: No reported disclosures. Background. Neonatal herpes simplex virus (NHSV) infection is rare but can cause a severe disease, even death. However, data on NHSV are limited in Asia. The aim of this study was to estimate the number of NHSV infection and evaluate the characteristics of NHSV infection in Korea where seroprevalence of HSV infection in child-bearing age women is not well known.
A Multicenter Study on Clinical Outcome of Symptomatic Neonatal Herpes Simplex Virus Infection in Korea
Methods. This is the first multicenter retrospective study in 12 university hospitals in Korea. From January 2008 to December 2017, neonates ≤ 28-day old with confirmed HSV infection were identified and a chart review was performed.
Results. Among 12 medical centers, 16 patients were identified in six centers. Eight (50%) patients were male and median age at admission was 11.1 days (range, 0-28 days). Ten (63%) patients were positive for HSV 1 and six (37%) patients were HSV 2 positive. Four (25%) patients were classified as disseminated HSV. Eleven (69%) patients were diagnosed as central nervous system (CNS) disease. One (6%) patient had skin, eye, and/or mouth (SEM) disease. All the patients received intravenous acyclovir and median treatment duration was 19 days (range 3-68 days). Five (35%) patients received additional suppressive therapy and median treatment duration was 131.4 days. Four patients (25%) developed seizure (one in disseminated and three in CNS disease) and two of them recovered without neurologic complications. Two (12.5%) patients with disseminated disease died within 30 days from the diagnosis and one of them had a maternal history of previous genital herpetic lesion. There was no mention on maternal history of genital herpes in 10 (63%) patients in the medical records.
Conclusion. Although not common, NHSV infection occurs in Korean babies with high 30-day mortality rate of 12.5%. Increased awareness is warranted among Korean pediatricians to take a thorough maternal history of genital herpes infection.
Disclosures. Background. Elvitegravir (EVG)/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is approved for treatment of HIV-1 in children weighing ≥25 kg based on a Gilead sponsored study of safety, pharmacokinetics (PK), and antiviral activity among 23 virologically suppressed (VS) children 6-<12 years old who switched from a stable antiretroviral (ARV) regimen to E/C/F/TAF. All subjects were perinatally infected with HIV. Though all subjects maintained HIV viral load < 50 copies/mL, a decrease in mean CD4+ cell count (CD4ct) occurred at Week 2 and persisted to Week 24 (Table 1) . Methods. We explored possible reasons for CD4ct declines including change in overall leukocyte and absolute lymphocyte count (ALC), relationship between CD4ct and PK of each drug in E/C/F/TAF, and trends in subject-level CD4ct. We reviewed prior ARV trials and literature to look for drug class effects.
Results. Decreased CD4cts were not explained by declines in total leukocyte counts or ALC. There was no association between CD4ct and area under the curve (AUC) of any of the four drugs. Mean CD4ct decline was not driven by a few outliers; CD4ct declined in 21/23 subjects. Prior ARV trials of VS adults and children, including EVG-containing regimens, show no notable sustained decline in CD4ct. Pediatric studies of other integrase inhibitors (INSTI) in this age group did not have comparable VS subjects. The literature describes structural similarity between human recombinant activation gene (RAG)1/2 and HIV integrase. RAG inhibition by INSTIs could potentially interfere with B and T cell development. EVG exposure in mice at supra-therapeutic concentrations, caused significant reductions in mature B lymphocytes. The relevance of this finding to humans is unclear.
Conclusion. Decreased CD4ct is a unique finding in this pediatric study of E/C/F/TAF and the etiology remains unclear. Inhibition of RAG1/2 by EVG may play a role, but further research is needed. No subjects had nadir CD4ct < 350 and no opportunistic infections were reported. However, CD4 declines are included in E/C/F/TAF labeling to alert providers of this potential risk.
Disclosures. Background. In 2015, over half of sexually transmitted infections (STI) and 22% of new HIV infections were among youth aged 15-24. Latest Utah data from 2014 showed this group accounted for 62% of chlamydia, 33% of gonorrhea, and 12% of new HIV infections. HIV testing in Utah is low with 24.2% of adults ever tested. There have been no studies published evaluating Utah HIV testing rates in youth.
Methods. An anonymous email-based survey was sent to 396 youth providers in Utah during an 8-week span in 2017. 102 (26%) responded and analysis was limited to 83 (21%) providers who reported caring for patients aged 15-24.
Results. The median age of providers was 35.5; median years out of residency 8.5; most were female (54%); self-identified as Caucasian (86%); attending level physicians (70%) and many (61%) practiced in urban settings. Over half identified as moderately, very, or extremely comfortable screening for HIV. Approximately 75% were familiar with CDC HIV testing guidelines. However, only 16% report always or often testing youth for HIV. Providers were more likely to screen for HIV in older patients; 19% always or often screening patients age 17-24 and 10% of patients age 13-16. Factors that increased the likelihood of offering an HIV test included: patient request, men who report sex with men, prior STI or a history of injection drug use (Figure 1) . Common reasons for rarely or never offering testing included: belief the patient panel is not sexually active, low prevalence of HIV and provider discomfort in discussing sexual behaviors (Figure 2 ). Less than one-third of providers reported familiarity with the CDC's PrEP guidelines, but most (91%) expressed interest in more information. Provider discomfort in offering PrEP was highest in the younger patients (Figure 3) . The same factors that increased the likelihood of testing for HIV held true for prescribing PrEP.
Conclusion. In Utah, the majority of providers are familiar with CDC HIV testing guidelines; however, testing remains low. This may be due to misconceptions around HIV risk and provider comfort. This is a missed opportunity for early detection of HIV in a population with known high rates of other STIs. Youth providers are not familiar with PrEP but they would like further education.
Disclosures. All authors:
No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Seasonal influenza infection is associated with secondary bacterial complications involving the upper and lower respiratory tract. However, the association of influenza infection with secondary severe or complicated head and neck infections is not appreciated.
Methods. We performed a retrospective review of pediatric patients hospitalized at Texas Children's Hospital with bacterial head or neck infections following influenza infection from October 2017 to March 2018. We queried the infectious diseases consult database using the search terms: orbital cellulitis, mastoiditis, retropharyngeal abscess,
